Clementia Pharmaceuticals was a Montreal-based rare disease biopharmaceutical company founded in 2011. Its lead compound palovarotene, a retinoic acid receptor gamma agonist, was in clinical development for fibrodysplasia ossificans progressiva and multiple osteochondromas. Clementia was acquired by Ipsen in 2019 for approximately $1.3 billion.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2017
Jun 2015
Jan 2015
Jan 2014
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
